|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, April 23, 2016 ) The Chronic Obstructive Pulmonary Disease Industry Report shows that persistent breathing difficulties and repeated exacerbations of COPD symptoms make the disease one of the leading causes of morbidity and the fifth-leading cause of death in the world. COPD is linked to cumulative exposure to risk factors, primarily tobacco smoke, but also environmental pollutants. The COPD marketed products landscape consists of pharmacological therapies aimed at managing the symptoms associated with COPD, although none of the available therapies have been shown to modify long-term disease progression. The current COPD pipeline consists of 212 active products in development. Initial analysis revealed a small presence of first-in-class products, constituting 16.5% of the pipeline. In comparison to other indications, this is relatively low; however, there are some promising trends within COPD product development.
Other Key Points in Report:
The COPD market has benefited from notable additions in recent years.
-Which classes of drug dominate the market?
-What additional benefits have newly approved therapies brought to market?
-How do the leading marketed therapies compare clinically?
The pipeline contains a range of molecule types and molecular targets, including those that are well established in COPD and novel, first-in-class therapies.
-Which molecular targets appear most frequently in the pipeline?
-To what degree is the pipeline penetrated by first-in-class innovation?
-Which target families consist of the most first-in-class products?
First-in-class products differ substantially in their clinical potential, based on their alignment to disease causing pathways.
-How well are first-in-class targets aligned to known disease causing pathways?
-Which targets are specifically found in early-stage development?
-What is the industry-wide interest in these targets?
-Which are the most promising first-in-class targets in early-stage development?
Inquire before Buying Report@ http://www.reportsweb.com/inquiry&RW0001170039/buying
Table of Content: An Overview
2 Executive Summary 4
2.1 Unmet Needs Remain in COPD Market 4
2.2 First-in-Class Innovation Beginning to Emerge in COPD 4
2.3 COPD Lags Behind Asthma in First-in-Class Innovation 4
3 The Case for Innovation in COPD 5
3.1 Growing Number of Opportunities for Biologic Products 6
3.2 Diversification of Molecular Targets 6
3.3 Innovative First-in-Class Product Developments Remain Attractive 6
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 7
3.5 Sustained Innovation 7
3.6 GBI Research Report Guidance 8
4 Clinical and Commercial Landscape 9
4.1 Disease Overview 9
4.1.1 Epidemiology 9
4.1.2 Symptoms 9
4.1.3 Etiology 9
4.1.4 Pathophysiology 9
4.1.5 Diagnosis 11
4.1.6 Assessment of Disease Severity 11
4.1.7 Treatment 12
4.1.8 Treatment Algorithm 14
4.2 Overview of Marketed Products 14
4.2.1 Molecule Type and Target Analysis 15
4.2.2 Quick Relief Medication 15
4.2.3 Bronchodilator and Inhaled Corticosteroid Combination Therapy 15
4.2.4 Bronchodilator Monotherapy 16
4.2.5 Bronchodilator Combination Therapy 17
4.2.6 Alternative Therapy 17
4.2.7 Conclusion 17
4.2.8 Unmet Needs 18
Ask for Discount on Report @ http://www.reportsweb.com/inquiry&RW0001170039/discount
5 Assessment of Pipeline Product Innovation 19
5.1 Molecular Target Analysis 21
5.2 Comparative Distribution of Programs between COPD Market and Pipeline by Therapeutic Target Family 26
5.3 First-In-Class Pipeline Programs Targeting Novel Molecular Targets 26
6 Signaling Pathways, Disease Causation and Innovation Alignment 30
6.1 The Complexity of Signaling Networks in COPD 30
6.2 Signaling Pathways and First-in-Class Molecular Target Integration 30
6.3 First-in-Class Target Matrix Assessment 31
7 First-in-Class Target Evaluation 33
7.1 Pipeline Programs Targeting Toll-Like Receptor 3 33
7.2 Pipeline Programs Targeting Adenosine A(2B) Receptor 34
7.3 Pipeline Programs Targeting Prostaglandin D2 Receptor 2 34
7.4 Pipeline Programs Targeting P-selectin 35
7.5 Pipeline Programs Targeting Macrophage Metalloelastase 35
7.6 Pipeline Programs Targeting Rho Associated Protein Kinase 1 36
7.7 Pipeline Programs Targeting Soluble Epoxide Hydrolase 37
7.8 Pipeline Programs Targeting Vasoactive Intestinal Peptide Receptor Family 37
7.9 Conclusion 38
8 Deals and Strategic Consolidations 39
8.1 Industry-Wide First-in-Class Deals 39
8.2 Licensing Deals 40
8.3 Co-development Deals 43
8.4 First-in-Class Programs not Involved in Licensing or Co-Development Deals 45
Purchase Complete Report @ http://www.reportsweb.com/buy&RW0001170039/buy/6995
About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
